If you are about to commit a nine-figure budget to a program, you should have a diligence-grade memo that integrates human evidence, mechanism, clinical history, and competitive risk into a single recommendation.
A 30 to 60 page Target and Indication Investment Memo that leadership can use to defend a decision to governance, partners, or investors.
Clear recommendation
Go, no-go, or conditional, plus kill criteria and what would change the call.
Human evidence and plausibility
Genetics and human data integrated with mechanism and translational relevance.
Competitive and failure history
What has been tried, what failed, and where differentiation is realistic.
When this is most valuable is right before major capital allocation.
30 minute kickoff to align on the decision, timeline, and what evidence would change the call.
Integrate genetics, biology, trial history, and competitive intelligence into a coherent memo with a risk register.
Walk leadership through the memo, pressure test assumptions, align on recommendation and next-step actions.
If you share internal readouts under NDA, we incorporate them and clearly separate internal vs public evidence.
No. This is diligence on a specific decision. If you want to discover novel targets at scale, you want a platform. If you want to decide whether to bet on a target and indication, you want a diligence memo.
We make it explicit. The memo includes evidence quality, assumptions, and what experiments or data would be decision-changing. This is often the most valuable part for governance.
Start with a Rapid Kill Screen on one controversial program. If the output is useful, the Full Investment Memo becomes an easy next step.
Send the target, indication, and decision deadline. We will propose the right scope and give a fixed price. If you are prepping a board meeting, portfolio review, fundraising, or partner diligence, this usually pays for itself.